SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC — Stella

Recruiting

Back to Breast Cancer Early Stage Breast Cancer (Stage 1-3) trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Henan Cancer Hospital, Zhengzhou, Henan

Key details

Phase

Safety & dosing

Sponsor

Henan Cancer Hospital

Enrollment target

~180 participants

Started

April 2025

Primary completion

May 2029

Age range

18 Years – 70 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov